Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05124392 · ClinicalTrials.gov registry record
Biomarker Profiling in Individuals at Risk for Prion Disease
A clinical trial of CJD (Creutzfeldt Jakob Disease) and Prion Diseases, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT05124392: Recruiting study of CJD (Creutzfeldt Jakob Disease) and Prion Diseases, sponsored by Massachusetts General Hospital.
NCT05124392 is a study of CJD (Creutzfeldt Jakob Disease) and Prion Diseases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05124392, a study of CJD (Creutzfeldt Jakob Disease) and Prion Diseases, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.
Primary Outcome
Levels of YKL40
Conditions Studied
Study Locations (1)
Massachusetts
- Alzheimer's Clinical and Translational Research Unit - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2027-06-01 |
What NCT05124392 shows while recruiting
NCT05124392 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 5 conditions, with CJD (Creutzfeldt Jakob Disease) appearing as the primary indexed condition, and to 0 interventions.
NCT05124392 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05124392 about?
NCT05124392 is a clinical study titled "Biomarker Profiling in Individuals at Risk for Prion Disease". We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.
What is the current status of trial NCT05124392?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2017-12-01. Estimated completion is 2027-06-01.
What conditions does trial NCT05124392 study?
This clinical trial studies the following conditions: CJD (Creutzfeldt Jakob Disease), Prion Diseases, GSS, FFI, Familial Fatal Insomnia.
Who is sponsoring clinical trial NCT05124392?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05124392 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI